旨在评估患有转移性前列腺癌 (mPC) 的男性接受雄激素剥夺疗法 (ADT) 标准护理治疗的频率。使用加州癌症登记数据确定了 2010 年至 2018 年间新诊断的 mPC（IV 期）年龄≥20 岁的男性。在诊断时根据患者/肿瘤特征检查是否接受激素治疗作为初始癌症治疗。进行卡方检验和逻辑回归（针对协变量进行调整），以评估接受激素治疗与患者/肿瘤特征之间的关联。我们确定了 13,680 名新诊断 mPC 的男性，其中 3637 名仅出现局部转移 (N1)，而 9596 名则出现局部转移 (N1)。伴有或不伴有 N1 疾病的远处转移 (M1)。 21.8% (n = 2980) 的男性没有接受 ADT。接受 ADT 的比例最高的是 75-84 岁的男性（81.6%），最低的是 85 岁以上的男性（76.0%）。亚洲男性接受 ADT 的比例最大（n = 962，81.5%），其余亚组接受 ADT 的男性比例相似（76.8% 至 77.2%）。对协变量进行调整后，回归结果显示，格里森评分较高 (8-10) 的男性更有可能接受 ADT（OR 2.04, 1.82-2.27，p = < 0.001）以及远处转移性疾病的男性 (OR 4.02, 3.62-4.46, p = < 0.001)。居住在社会经济地位最低社区的男性接受 ADT 的可能性最低（OR 0.79, 0.68-0.93, p = 0.0032）。种族/民族在接受 ADT 方面没有观察到差异。尽管近年来 mPC 的治疗取得了显着进步，但超过五分之一的患者没有接受 ADT，而 ADT 是所有新的全身疗法的支柱。该数据集可能有助于解决加利福尼亚州的一些前列腺癌护理差异。© 2023。作者，获得 Springer Nature Limited 的独家许可。

To evaluate how often men with metastatic prostate cancer (mPC) receive standard of care treatment with androgen deprivation therapy (ADT).Men aged ≥20 years with newly diagnosed mPC (stage IV) between 2010 and 2018 were identified using California Cancer Registry data. Receipt of hormonal therapy as initial cancer treatment was examined by patient/tumor characteristics at time of diagnosis. Chi-square tests and logistic regression, adjusted for covariates, were performed to assess association between receipt of hormonal therapy and patient/tumor characteristics.We identified 13,680 men with newly diagnosed mPC, of which 3637 had local metastasis (N1) only while 9596 had distant metastasis (M1) with or without N1 disease. 21.8 % (n = 2980) of men did not receive ADT. The highest rate of receiving ADT was among men between ages 75-84 (81.6%) and the lowest rate was in men over 85 (76.0%). Asian men had the largest proportion receiving ADT (n = 962, 81.5%) with remaining subgroups having similar proportion of men receiving ADT (76.8% to 77.2%). Once adjusted for covariates, regression results showed men with a higher Gleason score (8-10) were more likely to receive ADT (OR 2.04, 1.82-2.27, p = < 0.001) as well as men with distant sites of metastatic disease (OR 4.02, 3.62-4.46, p = < 0.001). Men residing in neighborhoods with the lowest socioeconomic status were least likely to receive ADT (OR 0.79, 0.68-0.93, p = 0.0032). No differences in receipt of ADT were observed by race/ethnicity.Despite significant advancements in the treatment of mPC in recent years, over one-fifth of patients did not receive ADT, which is the backbone for all new systemic therapies. This dataset might help address some of the prostate cancer care disparities in California.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.